Retatrutide GLP-3 Capsules – 30 Capsules | Pre-order

Retatrutide at a glance

Retatrutide is a synthetic peptide described in the scientific literature as a triple agonist at the receptors for GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide 1) and glucagon. The sequence is derived from native GIP and carries a lipidated side chain, which the literature associates with albumin binding and an extended half-life. This product is offered as pre-orderable research reference material in a laboratory formulation consisting of 30 capsules – for example for questions relating to formulation and stability analysis or to the comparative characterisation of dosage matrices in the laboratory.

Molecule profile

• Class: synthetic, lipidated GIP-based peptide
• Mechanism as described in the literature: agonism at GIP, GLP-1 and glucagon receptors
• Typical research fields: receptor pharmacology, incretin and glucagon signalling pathways, formulation and stability analysis

Product details

• Form: research formulation in capsules
• Pack size: 30 capsules
• Status: pre-order
• Batch-specific analytical documentation for the batch delivered

Research context

In research models, retatrutide is examined with regard to the combined activation of GIP, GLP-1 and glucagon receptors and the cellular and metabolic signalling pathways associated with it. Published work addresses, among other things, the receptor selectivity of the molecule at the three target receptors and comparative questions concerning mono-, dual- and triple agonists of the incretin class. The capsule formulation additionally opens up analytical questions around matrix effects, content determination and the stability of a solid dosage matrix – always with reference to laboratory analysis, not to any use outside the laboratory.

What does “GLP-3” mean?

“GLP-3” is not a hormone in its own right but a widely used informal term for the third generation of incretin-based research peptides: GLP-1 mono-agonists (for example semaglutide) were followed by dual GIP/GLP-1 agonists (for example tirzepatide), and retatrutide adds the triple agonist that also addresses the glucagon receptor. Anyone searching for “GLP-3 capsules” is normally referring to retatrutide as a research formulation. Peptélia carries Retatrutide GLP-3 both as a capsule formulation and as a peptide in 5, 10 and 15 mg – each with batch-specific analytical documentation.

Ordering from Peptélia

• Dispatched from Germany on the next business day
• Delivery times vary by destination
• Free shipping on orders over €100
• Batch certificate of analysis viewable before purchase
• Discreet, unbranded packaging

Quality & documentation

Only the product-specific details and the certificate of analysis for the batch actually delivered are authoritative. Statements on identity, purity, stability or composition apply only insofar as they are supported by that documentation. Every batch ships with a batch-specific certificate of analysis (COA). Purity is determined by HPLC; identity and analytical data are provided for complete laboratory documentation. How to read and check such a certificate is explained in our COA guide; details of the testing process can be found on the Quality & laboratory testing page.

Important note

The capsule form does not imply any suitability for ingestion or other use. All substances offered by Peptélia are intended exclusively for scientific use in the laboratory (research use only). They are not medicinal products, not food supplements and not cosmetics. Use in humans or animals, as well as any diagnostic or therapeutic use, is expressly excluded.

For research use only. Not for use in or on the human body.